Mergers and Acquisitions

Thermo Fisher Scientific adds Advanced Scientific’s custom single-use systems and equipment to its bioprocessing offerings.

Roivant Neurosciences acquired GlaxoSmithKline’s selective 5-HTC receptor antagonist for the treatment of various neurological disorders, specifically Alzheimer’s disease.

Merck announced that it acquired OncoEthix, a biotechnology company specializing in oncology drug development, for up to $375 million.

Roche will use Dutalys’ DutaMab technology for the engineering of bispecific therapeutic antibodies.

Roche will use Dutalys’ DutaMab technology for the engineering of bispecific therapeutic antibodies.Roche Acquires Bispecific Antibody Developer Dutalys

Fujifilm Diosynth Biotechnologies announced the completion of the acquisition of Kalon Biotherapeutics, a company that specializes in advanced biologics development manufacturing.

The acquisition will enhance Merck's "superbug" medication portfolio.Merck announced Dec. 8, 2014 that it would acquire Cubist Pharmaceuticals for a total transaction value of approximately $9.5 billion, including a little over $1 million in debt. The deal will add to Merck’s portfolio of drugs treating antibiotic-resistant bacteria, such as Cubist’s antibiotic Cubicin (daptomycin for injection), the only approved once-a-day therapy for both Staphylococcus aureus bacteremia and complicated skin and skin structure infections.

MedImmune enters into an agreement to acquire the image analysis and data mining company.

Acorda Therapeutics acquired Civitas Therapeutics for $525 million, giving Acorda all the rights to CVT-301, a Phase III candidate for off episodes of Parkinson?s disease.

PCI's acquisition of Biotech Services International expands the packaging services provider's presence in Europe.

DPT Laboratories acquired Media Pharmaceuticals' Lakewood, New Jersey facilities, providing space for aseptic processing suites and filling equipment.

PSC Investments announces the acquisition of a high potency, sterile fill/finish pharmaceutical manufacturing facility.

Genia's DNA-sequencing platform will strengthen Roche's pipeline.

Provence Technologies? strengthens its expertise in therapeutic chemistry with acquisition of Synprosis.

Aastrom acquires Sanofi's CTRM business unit for $6.5 million.

Repligen acquired Refine Technology and its Alternating Tangential Flow system for continuous bioprocessing.

KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.

Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.

Tigermed acquires Frontage Laboratories for $50.25 million.

BMS acquisition of iPierian advances BMS' pursuit of therapeutics for genetically defined diseases.

Sartorius Stedim Biotech's acquisition of AllPure Technologies will extends its portfolio for single-use bioprocessing.

Aastrom Biosciences will acquire Sanofi's CTRM business for $6.5 million.

Eurofins acquires DDS business of Merck KGaA in order to expand discovery solutions and bioanalytical services.

GE acquires Thermo Fisher-s HyClone cell culture media and sera products, gene modulation technologies, and magnetic beads businesses.

MedImmune expands its antibody-drug conjugate capability through acquisition and collaboration.